癌症（英文版）2016，Vol.35Issue(12)：699-705,7.DOI:10.1186/s40880-016-0140-0
Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
Yun Leng 1Wenming Chen 1Lugui Qiu 2Jian Hou 3Yaozhong Zhao 2Xuejun Zhang 4Shifang Yang 5Hao Xi 3Zhongxia Huang 1Ling Pan6
作者信息
- 1. Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing 100020, P. R. China
- 2. Department of Lymphoma Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, P. R. China
- 3. Department of Hematology, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai 200003, P. R. China
- 4. Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, P. R. China
- 5. Beijing Sunbio Biotech Co., Ltd., Beijing 100176, P. R. China
- 6. Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, P. R. China
- 折叠
摘要
关键词
Recombinant human circularly permuted TRAIL/Phase II trial/Relapsed or refractory multiple myeloma/Effcacy/SafetyKey words
Recombinant human circularly permuted TRAIL/Phase II trial/Relapsed or refractory multiple myeloma/Effcacy/Safety引用本文复制引用
Yun Leng,Wenming Chen,Lugui Qiu,Jian Hou,Yaozhong Zhao,Xuejun Zhang,Shifang Yang,Hao Xi,Zhongxia Huang,Ling Pan..Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma[J].癌症（英文版）,2016,35(12):699-705,7.
